Japanese surgical AI startup Anaut raises Series B for global push
What's the deal? Anaut, a Tokyo-based startup building AI-powered surgical visual assistance tools, has closed a Series B round to fund its international expansion and continued product development. The company, founded by surgeon Naoshi Kobayashi, develops the EUREKA series — software that provides real-time visual recognition support to surgeons during operations.
The round closed in two tranches — March and May 2026 — led by Japan Growth Capital Investment Corporation (managed by Nomura Sparks Investment). New investors include the Japan Bank for International CooperationDealroom has a profile for this one. Try Dealroom →, the Green Finance Organisation, and Vision IncubateDealroom has a profile for this one. Try Dealroom →. Existing backers Beyond Next Ventures, ANRI, and KSP also participated. The company did not disclose the total amount raised.
Anaut plans an extension round this summer, targeting overseas VCs, including venture arms of international hospitals.
Why now? The startup hit a string of regulatory milestones that make expansion viable. Its flagship product, EUREKA α, received manufacturing and marketing approval from Japan's Ministry of Health in April 2024 — a world first for real-time surgical visual assistance AI. In January 2025, it secured additional approval covering pancreatic and nerve surgery.
Anaut established a US subsidiary, Anaut America Inc., in 2025 and plans to open a European entity this summer. It is pursuing FDA clearance and CE marking in parallel.
What could go wrong? Medical device regulation is notoriously slow and unpredictable, especially across multiple jurisdictions. Securing FDA approval and CE marking while simultaneously scaling commercial operations in Japan will stretch the team and the balance sheet. The company's decision not to disclose its raise also makes it harder to gauge whether it has enough runway for what amounts to a three-continent regulatory and commercial push.
Competition is heating up, too. Surgical AI is drawing significant investment globally, with players in the US and Europe already well-established in adjacent spaces like robotic surgery and computer vision.
The signal: Anaut's undisclosed Series B — backed by a mix of state-linked institutions and growth-stage funds — underscores Japan's increasing willingness to mobilise public capital behind deep-tech medical exports. The Japan Bank for International Cooperation's participation, typically reserved for infrastructure and trade finance, suggests a policy-level bet on surgical AI as a category Japan can own globally. With domestic adoption already underway and a "Eureka Inside" integration play aimed at next-generation surgical devices, Anaut is positioning itself not just as a software vendor but as an embedded intelligence layer for the operating room.
Read more: prtimes.jp
